it’s time pharmaceutical companies tobacco momentelected officials made lot noise cost prescription drugs must demand answers pharmaceutical companiesthe editorial board represents opinions board editor publisher separate newsroom oped sectiontwentyfive years ago congress hauled top executives nation’s seven largest tobacco companies forced make number longoverdue admissions cigarettes — including might cause cancer heart disease executives suppressed evidence addictive potential one dramatic exchange pressed representatives henry waxman ron wyden executives denied products addictive admitted would want children use themthe hearing ushered public health victory ages wake lawmakers health officials enacted measures would ultimately bring smoking rates united states alltime lowwith seven pharmaceutical executives set testify senate finance committee tuesday one hope similarly pivotal moment prescription drug prices like predecessors tobacco industry drug makers testify time nearuniversal anger industry anticsdrug prices soaring way defies reason vial insulin cost less  decade ago sells closer    actimmune drug treats severe malignant osteopetrosis sells less  onemonth supply britain costs   onemonth supply united states prices many drugs — treat cancers high blood pressure allergies — risen much average consumers rationing them grave peril even experts seem know prices set keep rising industry’s explanations — entities america’s byzantine health care system blame price increases products expensive risky make — tough swallow given drug companies’ conspicuous profit margins response crisis soaring drug prices meager best — duplicitous worst last year several companies agreed hold planned price increases six months president trump chastised twitter companies aggressively resisted state federal efforts enact formal changes drug pricing rulesmr trump kept campaign promise “negotiate like crazy” drug makers lower cost products statement last may industry would soon announce “voluntary massive” price cuts came naught bluster issue along blueprint resolving it least helped keep spotlight pharmaceutical industry questionable practicesif members senate finance committee want make use spotlight here’s ask executives tuesdayhow determine list prices drugs decides factors go companies’ drugpricing formulas can’t formulas made public senators also ask olivier brandicourt chief executive sanofi — major insulin maker scheduled participate hearing — cost insulin continues rise year year given drug available roughly century many cases still enjoys patent protection friday senator chuck grassley nowsenator wyden ranking members finance committee opened investigation insulin prices what’s fair profit margin lifesaving products common lament among pharmaceutical executives without enough profit one drug companies can’t afford make next one that’s fair point still many leading companies enjoy billions dollars year pure profit even lives put risk want basic medications insurers subject percent cap profits administrative expenses congress consider similar requirement certain prescription drugs much spend research development dollars go pharmaceutical companies routinely argue drug prices high research development expensive successful drug preceded many failures industry critics however note good deal basic research funded federal government national institutes health drug makers many leading drug makers spend research dollars looking new uses existing drugs risky innovations independent studies show research development costs drug companies large enough explain high drug prices would drug need patents patent protection enables drug makers recoup money spend developing marketing new product experts agree leading drug makers gamed system applying dozens patents minor technical tweaks provide little clinical benefit stave competition decadestake humira treats inflammatory disorders like arthritis crohn’s disease bestselling prescription drug world two decades since drug came market maker applied patents according initiative medicines access knowledge currently protected competition patents richard gonzalez ceo abbvie company makes humira appear tuesday’s hearing justify practicewhat change senators must allow drug makers point finger elsewhere tuesday yes insurance companies entities play role drug cost crisis hearing them it’s pharmaceutical companies companies need take meaningful steps toward lowering drug prices finance committee members come prepared tuesday could finally force industry help relieve strainthe times committed publishing diversity letters editor we’d like hear think articles tips here’s email lettersnytimescomfollow new york times opinion section facebook twitter nytopinion instagraman earlier version editorial misstated number active patents humira abbvie company makes humira patents drug an earlier version editorial misstated condition thedrug actimmune prescribed severe malignant osteopetrosis malignant osteoperosis